AFT Pharmaceuticals outlines shareholder value focus in 2025 AGM

At its annual shareholders meeting in Auckland today, AFT Pharmaceuticals (ASX:AFP) laid out its plans to leverage the company’s R&D pipeline as it hunts out new addressable markets worth as much as US$8 billion.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

This content is disseminated in partnership with AFT Pharmaceuticals Ltd. It is intended to inform investors and should not be taken as financial advice.

AFT Pharma confirmed its guidance for FY26 at the same holders meeting, setting its operating profit at $20 to $24 million as it makes “good progress” toward $300M by FY27.

“We’re really excited about our R&D portfolio, we’ve got an extensive pipeline of eight patented pharmaceuticals, including some really interesting ones,” AFT’s managing director, Hartley Atkinson, told HotCopper.

Watch Mr Atkinson’s full Watchlist interview with HotCopper in the video above.

Join the discussion. See what HotCopper users are saying about AFT Pharmaceuticals Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.